5-(p-Methylphenyl)-5-phenylhydantoin
CAS : 51169-17-6
Ref. 3D-FM25927
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté | ||
250mg | Arrêté |
Informations sur le produit
- 5-(4-Methylphenyl)-5-phenyl-2,4-imidazolidinedione
- (5R)-5-(4-methylphenyl)-5-phenylimidazolidine-2,4-dione
- (5S)-5-(4-methylphenyl)-5-phenylimidazolidine-2,4-dione
- (±)-5-(4-Methylphenyl)-5-phenyl hydantoin
- 2,4-Imidazolidinedione, 5-(4-methylphenyl)-5-phenyl-
- 5-(4-Methylphenyl)-5-Phenylimidazolidine-2,4-Dione
- 5-Phenyl-5-(4-tolyl)hydantoin
- 5-Phenyl-5-(p-tolyl)hydantoin
- 5-Phenyl-5-(p-tolyl)imidazolidine-2,4-dione
- 5-p-Tolyl-5-phenylhydantoin
- Voir d'autres synonymes
- Hydantoin, 5-phenyl-5-p-tolyl-
- Mpph
- NSC 32105
5-(p-Methylphenyl)-5-phenylhydantoin (MPH) is a hydantoin derivative that has been used in the treatment of epilepsy and other neurological disorders. It is metabolized to phenytoin, its active form, with a half-life of about 10 hours. The clinical use of MPH was limited due to its high levels of toxicity and the need for frequent blood monitoring. A new analytical method has been developed for the determination of MPH in human serum. This method uses liquid chromatography coupled with chemical ionization, followed by mass spectrometry analysis. Validation studies have shown that this method is reliable and accurate for determining the concentration of MPH in human serum.